English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduMoffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone.
Tag: CAR T
Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.
Gut Microbiome Influences How Lymphoma Patients Respond to CAR T Therapy
In a new study published in Nature Medicine, Moffitt Cancer Center physician-scientists, in collaboration with four cancer centers in the United States and Germany, reveal how microorganisms in the gut influence non-Hodgkin lymphoma patient outcomes to a type of cellular immunotherapy called chimeric antigen receptor T-cell therapy, or CAR T.
Emily Whitehead, First Pediatric Patient to Receive CAR T-Cell Therapy, Celebrates Cure 10 Years Later
Ten years ago, Tom and Kari Whitehead came to Children’s Hospital of Philadelphia (CHOP) looking for a miracle. Their 6-year-old daughter, Emily, had relapsed in her battle with acute lymphoblastic leukemia (ALL), after many months of unsuccessful chemotherapy and a disease that had progressed so rapidly that she was ineligible for a bone marrow transplant to treat it. Her family came to CHOP in the hopes that Dr. Stephan Grupp, a pioneer in the field of cellular immunotherapy, could provide the miracle they were looking for.
Engineering CAR T Cells to Deliver Endogenous RNA Wakes Solid Tumors to Respond to Therapy
New study shows CAR T cells expressing RN7SL1 can activate the body’s natural immune cells against difficult-to-treat cancers
Moffitt Researchers Use Mathematical Modeling to Analyze Dynamics of CAR T-Cell Therapy
In an article published in Proceedings of the Royal Society B, Moffitt Cancer Center researchers use mathematical modeling to help explain why CAR T cells work in some patients and not in others.
Moffitt Researchers Identify Why CAR T Therapy May Fail in Some Lymphoma Patients
In a new study published in Blood, the official journal of the American Society of Hematology, Moffitt researchers show that immune dysregulation can directly affect the efficacy of CAR T therapy in patients with diffuse large B-cell lymphoma.
CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
Moffitt Researchers Create Chimeric Antigen Receptor Mutations to Enhance CAR T Cell Activity and Survival
Moffitt Cancer Center researchers are working to improve CAR T responses and make those responses more long-lasting for patients. In a new article published in Cancer Immunology Research, the team shares its findings, which show alterations to a specific domain of the chimeric antigen receptor enhances CAR T-cell activity and survival.
NCCN: What People with Cancer and their Caregivers Need to Know about CAR T-Cell Therapy
The National Comprehensive Cancer Network (NCCN) has published a new NCCN Guidelines for Patients: Immunotherapy Side Effects focused on chimeric antigen receptor (CAR) T-cell therapy. This is book two in a series that includes another book on irAEs focused on immune checkpoint inhibitors.
UCLA receives nearly $14 million from NIH to investigate gene therapy to combat HIV
UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.
Moffitt Cancer Center Study Suggests More Could Benefit from CAR T-Cell Therapy
Moffitt Cancer Center organized a consortium of 16 cancer treatment facilities across the U.S. that offer Yescarta as a standard-of-care therapy for patients with relapsed/refractory large B cell lymphoma. They wanted to determine if the safety and effectiveness seen in the ZUMA-1 clinical trial were similar for patients treated with the now commercially available CAR T therapy. Their findings were published in the Journal of Clinical Oncology.